| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/14/2013 | DE202012104963U1 Cetilistat aufweisende Zusammensetzungen Cetilistat containing compositions |
| 01/12/2013 | CA2781406A1 Method for improving exercise and recovery from exercise |
| 01/10/2013 | WO2013006864A2 Treating cancer with hsp90 inhibitory compounds |
| 01/10/2013 | WO2013006821A1 Systems, methods, and formulations for treating cancer |
| 01/10/2013 | WO2013006815A1 Methods and compositions to modulate antiviral and immune activity responses |
| 01/10/2013 | WO2013006809A2 Aerosolizing particles |
| 01/10/2013 | WO2013006808A2 Clavulanic acid for treatment of restless legs syndrome |
| 01/10/2013 | WO2013006795A2 Antiviral compositions and methods of their use |
| 01/10/2013 | WO2013006758A1 Diphosphate mimetics and uses thereof |
| 01/10/2013 | WO2013006738A1 Compounds for the treatment of hiv |
| 01/10/2013 | WO2013006737A1 Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| 01/10/2013 | WO2013006736A1 Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| 01/10/2013 | WO2013006734A1 Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity |
| 01/10/2013 | WO2013006729A2 Cannabinoid receptor binding agents, compositions and methods |
| 01/10/2013 | WO2013006658A1 Treatment of acetaminophen-induced liver damage by the administration of modulators of nitric oxide |
| 01/10/2013 | WO2013006643A1 Compositions and methods for treatment of symptoms in parkinson's disease patients |
| 01/10/2013 | WO2013006635A1 Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents for liver toxicity |
| 01/10/2013 | WO2013006619A1 Rna-yy1 interactions |
| 01/10/2013 | WO2013006596A1 Voltage-gated sodium channel blockers |
| 01/10/2013 | WO2013006532A1 Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer |
| 01/10/2013 | WO2013006526A2 Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
| 01/10/2013 | WO2013006485A1 Fused benzoxazepinones as ion channel modulators |
| 01/10/2013 | WO2013006463A1 Oxazepines as ion channel modulators |
| 01/10/2013 | WO2013006444A1 Compounds for inhibiting 1- deoxy-d-xylulose- 5 - phosphate reductoisomerase |
| 01/10/2013 | WO2013006408A1 Compounds and methods |
| 01/10/2013 | WO2013006400A1 Compounds for the treatment of addiction |
| 01/10/2013 | WO2013006372A1 Method of treating pathologic heterotopic ossification |
| 01/10/2013 | WO2013006368A1 Combination therapy |
| 01/10/2013 | WO2013006333A1 Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| 01/10/2013 | WO2013006308A2 Dihydropyrazoles |
| 01/10/2013 | WO2013006163A1 Oral rehydration composition |
| 01/10/2013 | WO2013006146A1 Effervescent formulations comprising dexketoprofen |
| 01/10/2013 | WO2013006135A1 Cough reducing product |
| 01/10/2013 | WO2013005836A1 Fructose absorption inhibitor |
| 01/10/2013 | WO2013005834A1 Anti-obesity agent comprising high-purity epa |
| 01/10/2013 | WO2013005798A1 Novel nitrogenated heterocyclic ring derivative |
| 01/10/2013 | WO2013005760A1 Adhesive skin patch containing serotonin receptor antagonist drug |
| 01/10/2013 | WO2013005755A1 Methylpiperidine derivative |
| 01/10/2013 | WO2013005753A1 Deuterated phenylpropionic acid derivative |
| 01/10/2013 | WO2013005403A1 Method for determination of onset sensitivity or onset resistance to heat stroke |
| 01/10/2013 | WO2013005379A1 Photodynamic therapy using photosensitizing agent or 5-aminolevulinic acid |
| 01/10/2013 | WO2013005354A1 Heterocyclic compound |
| 01/10/2013 | WO2013005281A1 Platelet-derived growth factor-bb production promoter, and mesenchymal stem cell production promoter, stem cell stabilizer and dermis regenerator each comprising same |
| 01/10/2013 | WO2013005226A1 A novel combined pharmaceutical composition containing diclofenac and methods of making and using the same |
| 01/10/2013 | WO2013005216A1 Compositions and methods for treatment of renal ischemia-reperfusion injury |
| 01/10/2013 | WO2013005170A2 Inhibitors of aquaglyceroporins, methods and uses thereof |
| 01/10/2013 | WO2013005168A2 Cannabinoid receptor modulators |
| 01/10/2013 | WO2013005157A1 Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer |
| 01/10/2013 | WO2013005154A1 Anticancer agent |
| 01/10/2013 | WO2013005153A1 Biaryl derivatives as nachr modulators |
| 01/10/2013 | WO2013005094A1 Acid addition salt of donepezil and pharmaceutical composition thereof |
| 01/10/2013 | WO2013005057A1 New compounds |
| 01/10/2013 | WO2013005049A1 N- (2 -aminophenyl) benzamide derivatives as histone deacetylase inhibitors |
| 01/10/2013 | WO2013005042A2 Anti-viral therapy |
| 01/10/2013 | WO2013005041A1 Tricyclic heterocyclic compounds as kinase inhibitors |
| 01/10/2013 | WO2013005037A1 Improvements in or relating to visual performance and/or macular pigmentation |
| 01/10/2013 | WO2013005017A1 Cannabinoids for use in the treatment of neurodegenerative diseases or disorders |
| 01/10/2013 | WO2013005001A1 Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome |
| 01/10/2013 | WO2013004999A1 Drug combinations and uses in treating a coughing condition |
| 01/10/2013 | WO2013004996A1 5- or 6 - substituted 3 - hydroxy - 2 ( 1h) - pyridinones as d-amino acid oxidase (daao) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain |
| 01/10/2013 | WO2013004995A1 Pyrimidinone compounds and their use |
| 01/10/2013 | WO2013004984A1 Tricyclic compounds for use as kinase inhibitors |
| 01/10/2013 | WO2013004965A1 Novel combination of n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide and folfox |
| 01/10/2013 | WO2013004871A1 Amides of 2-amino-1,3-propanediols and use thereof as ceramidase inhibitors |
| 01/10/2013 | WO2013004831A1 Dronedarone for the prevention of atrial fibrillation |
| 01/10/2013 | WO2013004830A1 Pharmaceutical composition and solid galenic form having a high dronedarone content, and method for preparing same |
| 01/10/2013 | WO2013004828A1 Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| 01/10/2013 | WO2013004827A1 Carboxylic acid derivatives having an oxazolo[5,4-d]pyridine ring |
| 01/10/2013 | WO2013004826A1 Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
| 01/10/2013 | WO2013004824A1 Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| 01/10/2013 | WO2013004818A1 Darunavir combination formulations |
| 01/10/2013 | WO2013004816A1 Darunavir formulations |
| 01/10/2013 | WO2013004785A1 Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators |
| 01/10/2013 | WO2013004776A1 Supply of substances upstream of the haemodialysis membrane, e.g. of acetylcysteine, in dialysis methods for removing protein-bonded toxins from the blood |
| 01/10/2013 | WO2013004766A1 Nk-1 receptor antagonists for treating corneal neovascularisation |
| 01/10/2013 | WO2013004740A1 Anticonvulsant activity of turmeric oil and bisabolene sesquiterpenoids |
| 01/10/2013 | WO2013004709A1 Indolylmaleimides as soft pan-pkc inhibitors |
| 01/10/2013 | WO2013004683A1 Hemostatic agent particularly for use in surgical procedures |
| 01/10/2013 | WO2013004669A1 Multivalent oligosaccharides |
| 01/10/2013 | WO2013004658A1 Formulations of 5-fluorocytosine and uses thereof. |
| 01/10/2013 | WO2013004642A1 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
| 01/10/2013 | WO2013004617A1 Pyrazolopyridines useful in the treatment of disorders of the central nervous system |
| 01/10/2013 | WO2013004591A1 Micronized crystals of atorvastatin hemicalcium |
| 01/10/2013 | WO2013004557A1 A molecule regulating activity of insulin degrading enzyme (ide) |
| 01/10/2013 | WO2013004556A1 A molecule regulating activity of insulin degrading enzyme (ide) |
| 01/10/2013 | WO2013004551A1 Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
| 01/10/2013 | WO2013004527A1 A molecule regulating activity of insulin degrading enzyme (ide) |
| 01/10/2013 | WO2013004525A1 A molecule regulating activity of insulin degrading enzyme (ide) |
| 01/10/2013 | WO2013004462A1 A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof |
| 01/10/2013 | WO2013004422A1 Topical compositions for use in the prevention and/or treatment of dermatitis |
| 01/10/2013 | WO2013004332A1 Substituted azaheterocycles for the treatment of cancer |
| 01/10/2013 | WO2013004291A1 Cyclic amine derivatives as ep4 receptor agonists |
| 01/10/2013 | WO2013004290A1 Cyclic amine derivatives as ep4 receptor antagonists |
| 01/10/2013 | WO2013004250A1 Chewing gum having sustained release of nicotine |
| 01/10/2013 | WO2013004190A1 Amino-propylene-glycol derivatives, preparation method and pharmaceutical composition and use thereof |
| 01/10/2013 | WO2013004177A1 Composition of active ingredient of traditional chinese medicine and use thereof |
| 01/10/2013 | WO2013004171A1 Use of c15-substituted andrographolide derivatives in preparation of anti-hepatitis b virus medicament |
| 01/10/2013 | WO2013004148A1 Method for preparation of 3-butoxy-2-pyrazineformamide and use thereof |
| 01/10/2013 | WO2013004141A1 3-alkoxy-substituted-2-pyrazinyl formamide compound and use thereof |
| 01/10/2013 | WO2013004123A1 Ibuprofen chewable tablet |